Phase I – First Administration to Humans

783 trials 323 recruiting

Filter these 783 trials by condition, country, sponsor and more.

Open in Search →

Phase 1 Study of PYX-106 in Solid Tumors Ended

2023-509686-21-00 Solid Tumors 2023-07-05
A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumors Ended

2022-500540-38-00 Non-small cell lung cancer Oesophageal squamous cell ca 2023-06-27
Safety and tolerability of CTH120, first-in-human phase I study encompassing three parts: Single and Multiple Ascending doses and potential … Ended

2022-502209-13-01 Fragile X syndrome 2023-06-23
A clinical study of MK-1403 in healthy men Ended

2023-504695-23-00 Atherosclerosis 2023-06-15
First-in-human study of SAR445611 in healthy adult participants Ended

2022-502923-23-00 Immune system diseases 2023-06-12
A study to learn how safe the study treatment BAY3401016 is, how it affects the body and how it moves into, through, and out of the body whe… Ended

2022-502319-12-00 Alport syndrome 2023-05-30
A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3813, a gr… Ended

2023-503734-47-00 Acromegaly 2023-05-26
A phase Ib study to investigate the safety and effect of BR-003 Ended

2024-516338-37-00 Patients planned for open or percutaneous posterior spi 2023-05-11
Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer (CheckVAC) Ended

2024-515966-14-00 advanced pancreatic cancer 2023-05-03
A Single-Ascending-Dose Study of MK-4318 in Healthy Participants Ended

2023-503360-16-00 Acute and chronic pain 2023-05-02
A Phase I study to evaluate the safety and dosimetry of 68Ga-labelled OncoFAP derivatives in patients with solid tumors Ended

2022-500902-16-00 Patients with breast cancer, colorectal cancer, oesopha 2023-04-27
A positron emission tomography (PET) study to assess where the radiotracer [11C]AZ14132516 goes in the body following administration to heal… Ended

2022-502843-36-00 Crohn's disease 2023-04-27
Safety, tolerability and effect of DLX-001 in healthy volunteers Ended

2023-503390-38-00 Unipolar depression (UD) 2023-04-14
Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteers Ended

2023-509515-89-00 Tuberculosis 2023-04-14
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ANDMULTIPLE… Ended

2024-517955-10-00 Healthy volunteers 2023-04-05
Phase I dose escalation study of DPPG2-TSL-DOX combined with hyperthermia in soft tissue sarcoma Ended

2023-507836-19-00 Locally advanced (unresectable) or metastatic soft tiss 2023-04-03
INCA 32459-101: A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies Ended

2022-501505-13-00 Metastatic melanoma 2023-03-31
A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of MK-3508 in Healthy Participants Ended

2022-502926-42-00 Respiratory syncytial virus infection 2023-03-30
A phase I of TG6050 in the treatment of patients with metastatic lung cancer Ended

2024-513093-22-00 Non-small cell lung cancer (NSCLC) 2023-03-27
A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination … Ended

2023-504855-28-00 advanced/metastatic solid tumors 2023-03-21
A Phase 1 Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission … Ended

2022-502241-99-00 Crohn's Disease 2023-03-20
OMX-0407 Phase I Study Ended

2024-514554-75-00 Previously treated unresectable solid tumours 2023-03-16
A Phase 1 Multicenter, Open Label, First-in-Human Dose Escalation Study of AFM28, a Bispecific ICE® that Targets CD123 and CD16A, in patient… Ended

2023-510021-16-00 Refractory/relapsed (R/R) CD123-positive acute myeloid 2023-03-08
A trial in patients with blood cancer and lymphatic system cancer looking at finding the optimal dose of BMF-219 Ended

2024-515744-23-00 Relapsed or refractory (R/R) Acute lymphoblastic leukem 2023-02-15